Anti-glyco-cmet antibodies and their uses
AssigneeGO Therapeutics, Inc.
InventorsHans WANDALL, Julia SCHNABEL, Edwin TAN, Richard Johnson MORSE, Jr., Aaron GROEN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to anti-glyco-cMET antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of cMET and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
Claims56
An anti-glyco-cMET antibody or antigen binding fragment that specifically binds to a cMET peptide PTKSFISGGSTITGVGKNLN (SEQ ID NO:285) that has been glycosylated with GalNAc on the serine and threonine residues shown with bold and underlined text (“the cMET glycopeptide”).
A chimeric antigen receptor (CAR), whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:348, SEQ ID NO:339, SEQ ID NO:340, or SEQ ID NO:
- 341.
A peptide of 13-30 amino acids in length comprising a cMET peptide comprising PTKSFISGGSTITGVGKNLN (SEQ ID NO:286), or a fragment thereof comprising amino acids corresponding to amino acids 9 and 10 of PTKSFISGGSTITGVGKNLN (SEQ ID NO:286).
A peptide of 13-30 amino acids in length comprising a cMET peptide PTKSFISGGSTITGVGKNLN (SEQ ID NO:285) that has been O-glycosylated on the serine and threonine residues shown with bold and underlined text, or a fragment thereof comprising amino acids corresponding to amino acids 9 and 10 of PTKSFISGGSTITGVGKNLN (SEQ ID NO:
- 285).
Dependencies are inferred from the claim text.